Vertex Pharmaceuticals (VRTX) Gets a Hold Rating from Leerink Partners

In a report issued on June 10, Geoff Porges from Leerink Partners maintained a Hold rating on Vertex Pharmaceuticals (VRTXResearch Report). The company’s shares closed last Friday at $193.02, close to its 52-week low of $192.88.

According to, Porges is a 3-star analyst with an average return of 4.8% and a 49.0% success rate. Porges covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, Assembly Biosciences, and Theravance Biopharma.

Currently, the analyst consensus on Vertex Pharmaceuticals is a Strong Buy with an average price target of $267.15, a 37.7% upside from current levels. In a report issued on June 11, Needham also maintained a Hold rating on the stock.

See today’s analyst top recommended stocks >>

Based on Vertex Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.72 billion and net profit of $653 million. In comparison, last year the company earned revenue of $1.52 billion and had a net profit of $603 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Based in Massachusetts and incorporated in 1989, Vertex Pharmaceuticals, Inc. is a biopharmaceutical company, which is engaged in the development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.